Outcome of the Board Meeting held on Friday, May 01, 2026 for conversion of 114000 warrants in to Equity Shares
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shelter Pharma's Board has approved the conversion of 114,000 convertible equity warrants held by 3 non-promoter investors into 114,000 fully paid equity shares. The conversion was at an issue price of ₹42.25 per warrant (face value ₹10 + premium ₹32.25), with investors paying the balance exercise price of ₹31.6875 per warrant (75% of issue price), totaling ₹36,12,375 received by the company. The original warrants were allotted in July 2025 as part of a preferential allotment of 88,08,000 warrants. Post-conversion, the company's paid-up equity capital increased from ₹16,61,17,920 to ₹16,72,57,920.
This conversion results in modest equity dilution of 114,000 shares (approximately 0.69% increase in share count) and brings fresh capital of ₹36.12 lakh to the company. The newly allotted shares will rank pari-passu with existing shares pending BSE listing approval.